Sensibilité in vitro des souches de Candida albicans d'Origine vaginale aux antifongiques chez une population marocaine consultant à l'Institut pasteur du maroc

European Journal of Scientific Research

Volumn 80, Issue 1, 2012, Pages 109-114

  Boura, Hasna ^a   Bennani, Houda ^b   Saile, Rachid ^b   Bouchrif, Brahim ^a   El Azhari, Mohamed ^a   Dersi, Nourredine ^a  

^a Institut Pasteur du Maroc   (Morocco)

^b FACULTÉ DES SCIENCES BEN M SIK   (Morocco)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84864112944     PISSN: 1450216X     EISSN: 1450202X     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Chassot F, Negri MFN, Svidzinski AE, Donatti L, Peralta RM, Svidzinski TIE, et al. Can Intrauterine contraceptive devices be a Candida albicans reservoir? Contraception 2008;77:355-9.
2. Eckert LO, Hawes E, Stevens CE, Koutsky LA, Eschenbach DA, Holmes K, et al. Clinical Manifestations, risk factors, management algorithm. Obstet Gynecol 1998;92:757-65.
3. Sobel JD, Zervos M, Reed BD et al. Fluconazole susceptibility of vaginal isolates obtained From women with complicated Candida vaginitis: Clinical implications. Antimicrob Agents Chemother 2003;47:34-38.
4. Anane S, Kaouech E, Zouari B, Belhadj S, Kallel K, Chaker E. Les candidoses vulvovaginales: facteurs de risque et particularités cliniques et mycologiques. J Mycol Med 2010;20:36-41.
5. Amouri I, Abbes S, Sellami H, Makni F, Sellami A, Ayadi A. La candidose vulvo-vaginale: revue. J Mycol Med 2010;20:108-15.
6. Grigoriou O, Baka S, Makrakis E, Hassiakos D, Kapparos G, Kouskouni E. Prevalence of clinical vaginal candidiasis in a university hospital and possible risk factors. Eur J Obstet Gynecol Reprod Biol 2006;126:121-5.
7. Sobel JD. Vulvovaginal candidosis. Lancet 2007;369:1961-71.
8. Hospenthal DR, Murray CK, Rinaldi MG. The role of antifungal susceptibility testing in The therapy of candidiasis. Diagn Micro-biol Infect Dis 2004;48:153-60.
9. Pappas PG, Rex JH, Sobel JD, Filler SG, Dismukes WE, Walsh TJ. Guidelines for Treatment of candidiasis. Clin Infect Dis 2004;38:161-89.
10. Khan ZU, Chandy R, Metwali KE. Candida albicans strain carriage in patients and Nursing staff of an intensive care unit: a study of morphotypes and resistotypes. Mycoses 2003;46:476-86.
11. Klepser ME. Antifungal resistance among Candida species. Pharmacotherapy 2001;21:124-32.
12. Runyoro DKB, Matee MIN, Ngassapa OD, Joseph CC, Mbwambo ZH. Screening of Tanzanian medicinal plants for anti-Candida activity. BMC Com Alternat Med 2006;30:6-11.
13. Subcommittee of Antifungal Testing of the European Committee on Antibiotic Susceptibility Testing of the European Society of Clinical Microbiology and Infectious Diseases. Method for the Determination of Minimum Inhibitory Concentration (MIC) by Broth Dilution of Fermentative Yeasts. (2002) EUCAST Discussion document E. Dis 7.1 ESCMID.
14. Cuenca-Estrella M, Lee-Yang W., Ciblak M. A. et coll. Comparative Evaluation of NCCLS M27-A and EUCAST Broth Microdilution Procedures for Antifungal Susceptibility Testing of Candida Species (2002). Antimicrob. Agents Chemothe, 46, 11, 3644-3647.
15. Cuenca-Estrella M, Moore C. B., Barchiesi F., et coll. Multicenter evaluation of the Reproducibility of the proposed antifungal susceptibility testing method for fermentative Yeasts of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antimicrobial Susceptibility Testing (AFST-EUCAST). (2003) Clin. Microbiol. Infect, 9, 6, 467.
16. CLSI Summary Minutes Subcommittee on Antifungal Susceptibility Tests Ŕ Tampa, Florida Ŕ 8 January 2005.
17. Horowitz JB. Mycotic vulvovaginitis: A broad overview. Am J Obstet Gynecol 1991;165:1188-1192.
18. Saporiti AM, Gomez D, Levalle S, Galeano M, Davel G, Vivot W, et al. Vaginal candidiasis: etiology and sensitivity profile to antifungal agents in clinical use. Rev Argent Microbiol 2001;33:217-22.
19. Sobel JD. Vulvovaginitis due to Candida glabrata. An emerging problem. Mycoses 1998;41:18-22.
20. Anane S, Kaouech E, Zouari B, Belhadj S, Kallel K, Chaker E. Les candidoses vulvovaginales: facteurs de risque et particularités cliniques et mycologiques. J Mycol Med 2010;20:36-41.
21. Grigoriou O, Baka S, Makrakis E, Hassiakos D, Kapparos G, Kouskouni E. Prevalence Of clinical vaginal candidiasis in a university hospital and possible risk factors. Eur J Obstet Gynecol Reprod Biol 2006;126:121-5.
22. Benchellal M, Guelzim K, Lemkhente Z, Jamili H, Dehainy M, Rahali Moussaoui D, et Al. La candidose vulvo-vaginale à l'hôpital militaire d'instruction Mohammed V (Maroc). J Mycol Med 2011;21:106-12.
23. Arzeni D, Del Poeta M, Simonetti O et al. Prevalence and antifungal susceptibility of Vaginal yeasts in outpatients attending a gynecological center in Ancona, Italy. Eur J Epidemiol 1997;13:447-50.
24. Fan SR, Liu XP. In vitro miconazole susceptibility and clinical outcome in vulvovaginalCandidiasis. Int J Gynaecol Obstet 2007;97:207-8
25. Panizo MM, Reviakina V, Dolande M, Selgrad S. Candida spp. in vitro susceptibility Profile to four antifungal agents. Resistance surveillance study in Venezuelan strains Med Mycol 2009;47:137-43.
26. Skrodeniene E, Dambrauskiene A, Vitkauskiene A. Susceptibility of yeasts to antifungal Agents in Kaunas University of Medicine Hospital. Medicina (Kaunas) 2006;42:294-9.
27. Erja C. Trends in antifungal susceptibility among swedish can-dida species bloodstream Isolates from 1994 to 1998: comparison of the E-test and the Sensititre Yeast One Colorimetric Antifungal Panel with the NCCLS M27 - a reference method. J Clin Microbiol 2001;39:4181-3.
28. Khosravi AR, Shokri H, Mansouri P, Katiraee F, Ziglari T. Candida species isolated from nails and their in vitro susceptibility to antifungal drugs in the department of Dermatology (University of Tehran, Iran). J Mycol Med 2008;18:210-5.
29. Ribeiro, M. A., R. Dietze, C. R. Paula, D. A. Da Matta, and A. L. Colombo. Susceptibility profile of vaginal yeast isolates from Brazil. Mycopathologia 2000. 151:5-10.